Protein Requirements Amongst Male Masters-Level Athletes Following a Cycling Exercise Bout As Determined by the Indicator Amino Acid Oxidation Technique
Launched by MCGILL UNIVERSITY · May 22, 2024
Trial Information
Current as of February 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the protein needs of male cyclists aged 65 and older who train regularly. The study aims to find out how much protein these athletes require to recover effectively after endurance training sessions. Traditionally, protein intake recommendations have been based on older methods, but this trial will use a newer, non-invasive technique called the Indicator Amino Acid Oxidation (IAAO) to get a more accurate measurement of protein needs.
To be eligible for the study, participants must be healthy male cyclists who train more than four days a week and have a stable body weight for the past six months. They should also have a body mass index (BMI) within a certain range. Participants will need to attend several sessions in a lab to help gather data on their protein requirements. It’s important to note that individuals with certain health conditions or those taking specific medications may not qualify for the study. Overall, this research could help improve dietary protein recommendations for older athletes, ensuring they get the nutrition they need for optimal performance and recovery.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 18.5\< BMI \<35 kg/m\^2
- • Overtly healthy masters level cyclists ≥65 years
- • Masters level cyclist training (\>4 days per week; \~100 km per week)
- • Body mass stable over previous 6-months
- • Availability for multiple metabolic trials (\~7 trials)
- • Ability to travel to and from laboratory facility
- Exclusion Criteria:
- • Recent history of weight loss or weight gain (\>5% body weight)
- • Uncontrolled hypertension
- • ≥2 chronic diseases (e.g. diabetes, osteoporosis, dyslipidemia)
- • Acute illness that could affect protein metabolism (HIV, renal dysfunction, influenza)
- • Currently using anti-inflammatory medications
- • Inability to adhere to study protocol (i.e., alcohol, caffeine, dietary restrictions)
- • Regular tobacco user
- • Illicit drug use
- • Habitually ingesting ≥3 g/kg/bw
About Mcgill University
McGill University, a prestigious research institution located in Montreal, Canada, is committed to advancing medical science through innovative clinical trials. Renowned for its rigorous academic standards and collaborative approach, McGill fosters a dynamic environment that integrates cutting-edge research with clinical practice. With a focus on improving patient outcomes, the university's clinical trials span a wide range of therapeutic areas, leveraging the expertise of its diverse faculty and state-of-the-art facilities. McGill University is dedicated to ethical research practices and the dissemination of knowledge, ensuring that findings contribute meaningfully to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0